SEC Comment Letter for iTeos Therapeutics, Inc. (CIK 0001808865) — Aug 25, 2022
iTeos Therapeutics, Inc. (CIK 0001808865)
Date: Aug. 25, 2022 · CIK: 0001808865 · Accession: 0000000000-22-009197
AI Filing Summary & Sentiment
File numbers found in text: 001-39401
Letter
United States securities and exchange commission logo August 25, 2022 Matthew Gall Chief Financial Officer iTeos Therapeutics, Inc. 321 Arsenal St Watertown , MA Re:iTeos Therapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2021 Filed March 23, 2022 File No. 001-39401 Dear Mr. Gall: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
August 25, 2022
Matthew Gall
Chief Financial Officer
iTeos Therapeutics, Inc.
321 Arsenal St
Watertown , MA
Re:iTeos Therapeutics, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2021
Filed March 23, 2022
File No. 001-39401
Dear Mr. Gall:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences